Old Web
English
Sign In
Acemap
>
authorDetail
>
William Herrick
William Herrick
Leidos
Cancer research
PI3K/AKT/mTOR pathway
MAPK/ERK pathway
Protein kinase B
Pathology
3
Papers
6
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Isoform- and phosphorylation-specific multiplexed quantitative pharmacodynamics of drugs targeting PI3K and MAPK signaling in xenograft models and clinical biopsies.
2021
Molecular Cancer Therapeutics
William Herrick
Casey L. Kilpatrick
Melinda G. Hollingshead
Dominic Esposito
Geraldine OSullivan Coyne
Andrea M. Gross
Barry C. Johnson
Alice P. Chen
Brigitte C. Widemann
James H. Doroshow
Ralph E. Parchment
Apurva K. Srivastava
Show All
Source
Cite
Save
Citations (0)
Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
2020
Journal of Clinical Oncology
Geraldine O’Sullivan Coyne
Andrea M. Gross
Eva Dombi
Cecilia Tibery
Amanda Carbonell
Naoko Takebe
Joanne Derdak
Dominique C. Pichard
Apurva K. Srivastava
William Herrick
Ralph E. Parchment
Staci Martin
Pamela L. Wolters
Patricia Whitcomb
Lawrence Rubinstein
James H. Doroshow
Alice P. Chen
Brigitte C. Widemann
Show All
Source
Cite
Save
Citations (6)
Pharmacodynamics of PI3K, MEK, and AKT inhibitors through isoform-specific measurements of MEK, ERK, AKT, and ribosomal protein S6 in needle biopsies.
2019
Journal of Clinical Oncology
William Herrick
Casey L. Kilpatrick
Dominic Esposito
Howard Stotler
Melinda G. Hollingshead
James H. Doroshow
Ralph E. Parchment
Apurva K. Srivastava
Show All
Source
Cite
Save
Citations (0)
1